According to NanoViricides's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
Year | P/S ratio | Change |
---|---|---|
2023 | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | |
2010 | N/A | |
2009 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | 3.04 | N/A | ๐บ๐ธ USA |
Merck MRK | 5.49 | N/A | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 1.99 | N/A | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.40 | N/A | ๐ฌ๐ง UK |
Novavax NVAX | 2.08 | N/A | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | 3.41 | N/A | ๐บ๐ธ USA |